Perceived Versus Verified Cancer History and Missed Opportunities for Donation in an Australian Cohort of Potential Deceased Solid Organ Donors.
Journal
Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
13
07
2021
revised:
30
08
2021
accepted:
15
09
2021
entrez:
20
1
2022
pubmed:
21
1
2022
medline:
21
1
2022
Statut:
epublish
Résumé
There is an imperative to maximize donation opportunities given ongoing organ shortages, but donor suitability assessments can be challenging. We analyzed an Australian cohort of potential deceased donors 2010 to 2013 to explore misclassification of cancer risk and potential strategies for improvement (decision support, real-time data linkage to existing data sets, and increasing risk tolerance). Cancer history perceived at referral was compared with verified cancer history in linked health records. Transmission risks were based on clinical guidelines. Potential donors declined due to cancer but verified low risk were missed opportunities; those accepted but verified high risk were excess-risk donors. Among 472 potentially suitable donor referrals, 132 (28%) were declined because of perceived transmission risk and 340 (72%) donated. Assuming a low-risk threshold, there were 38/132 (29%) missed opportunities and 5/340 (1%) excess-risk donors. With decision support, there would have been 5 (13%) fewer missed opportunities and 2 (40%) more excess-risk donors; with real-time data linkage, 6 (16%) fewer missed opportunities and 2 (40%) fewer excess-risk donors; and with increased risk tolerance, 6 (16%) fewer missed opportunities and 11 (220%) more excess-risk donors. Potential donors' cancer history is typically incomplete at referral. There are missed opportunities where decision support or more accurate cancer history could safely increase organ donors.
Sections du résumé
BACKGROUND
BACKGROUND
There is an imperative to maximize donation opportunities given ongoing organ shortages, but donor suitability assessments can be challenging.
METHODS
METHODS
We analyzed an Australian cohort of potential deceased donors 2010 to 2013 to explore misclassification of cancer risk and potential strategies for improvement (decision support, real-time data linkage to existing data sets, and increasing risk tolerance). Cancer history perceived at referral was compared with verified cancer history in linked health records. Transmission risks were based on clinical guidelines. Potential donors declined due to cancer but verified low risk were missed opportunities; those accepted but verified high risk were excess-risk donors.
RESULTS
RESULTS
Among 472 potentially suitable donor referrals, 132 (28%) were declined because of perceived transmission risk and 340 (72%) donated. Assuming a low-risk threshold, there were 38/132 (29%) missed opportunities and 5/340 (1%) excess-risk donors. With decision support, there would have been 5 (13%) fewer missed opportunities and 2 (40%) more excess-risk donors; with real-time data linkage, 6 (16%) fewer missed opportunities and 2 (40%) fewer excess-risk donors; and with increased risk tolerance, 6 (16%) fewer missed opportunities and 11 (220%) more excess-risk donors.
CONCLUSIONS
CONCLUSIONS
Potential donors' cancer history is typically incomplete at referral. There are missed opportunities where decision support or more accurate cancer history could safely increase organ donors.
Identifiants
pubmed: 35047659
doi: 10.1097/TXD.0000000000001252
pmc: PMC8759621
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1252Informations de copyright
Copyright © 2022 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
ANZ J Surg. 2019 Sep;89(9):1068-1074
pubmed: 30706681
Am J Transplant. 2011 Jun;11(6):1140-7
pubmed: 21645251
Transplantation. 2012 Feb 27;93(4):348-53
pubmed: 22258288
Transplantation. 2002 Nov 27;74(10):1409-13
pubmed: 12451241
Am J Transplant. 2014 Jun;14(6):1376-82
pubmed: 24712385
Clin Transplant. 2017 Sep;31(9):
pubmed: 28665524
J Nephrol. 2020 Apr;33(2):277-288
pubmed: 31399908
Am J Transplant. 2015 Oct;15(10):2562-4
pubmed: 26138032
Transpl Int. 2021 Sep;34(9):1667-1679
pubmed: 34448264
Transplant Direct. 2019 Oct 17;5(11):e504
pubmed: 31773057
JMIR Res Protoc. 2020 Oct 26;9(10):e18282
pubmed: 33104005
Transpl Infect Dis. 2020 Dec;22(6):e13437
pubmed: 32767859